Tauns Laboratories Inc (197A)

Currency in JPY
537.00
+3.00(+0.56%)
Closed·

197A Financial Summary

Key Ratios

P/E Ratio10.09
Price/Book3.38
Debt / Equity77.14%
Return on Equity52.12%
Dividend Yield5.21%
EBITDA8.71B
Fair ValueUnlock
Fair Value UpsideUnlock

Statements Highlights

Period Ending:
2023
30/06
2024
30/06
* In Millions of JPY (except for per share items)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 64.45%
Dividend Yield
5.21%
Industry Median 1.47%
Annualised payout
28.00
Paid unevenly
5-Years Growth
-
Growth Streak

Analyst Ratings

1 Buy
1 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 710.00
(+32.22% Upside)

Earnings

Latest Release
May 14, 2025
EPS / Forecast
19.14 / --
Revenue / Forecast
5.63B / 6.20B
EPS Revisions
Last 90 days

FAQ

What were Tauns Laboratories's earnings for the latest quarter?

The Tauns Laboratories EPS (TTM) is 64.45. Tauns Laboratories reported sales of 5,626.89, net income of 1,958.62, and EPS of 19.14 for the latest quarter.

What was Tauns Laboratories's net income for the latest quarter?

Tauns Laboratories's net income for the latest quarter was 1,958.62.

How did Tauns Laboratories's performance compare year-over-year in the latest quarter?

The company's revenue moved from 5,561.40 in the previous quarter to 5,626.89 in the latest quarter, and net income moved from 1,990.19 to 1,958.62 compared to the previous quarter.

What is Tauns Laboratories's net profit margin on a TTM basis?

Tauns Laboratories's trailing twelve months (TTM) net profit margin is 31.32%.

How does Tauns Laboratories's debt to equity ratio compare to industry standards?

Tauns Laboratories's total debt-to-equity ratio is 77.14%.

What is Tauns Laboratories's return on investment on a TTM basis?

Tauns Laboratories's trailing twelve months (TTM) return on investment (ROI) is 52.12%.

What were Tauns Laboratories's total assets and liabilities in the latest quarter?

As of the latest quarter, Tauns Laboratories reported total assets of 37,635.13 million and total liabilities of 10,849.68 million.

How has Tauns Laboratories's total revenue grown this year?

Tauns Laboratories's total revenue was 5,561.40 in the previous quarter and 5,626.89 in the latest quarter.

What is Tauns Laboratories's gross margin on a TTM basis?

Tauns Laboratories's trailing twelve months (TTM) gross margin is 70.53%.

What was Tauns Laboratories's revenue per share for the latest quarter?

Tauns Laboratories's revenue per share for the latest quarter was 1,678.28.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.